4DMT Announces New Employment Inducement Grants
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) reported that on July 14, 2026, the board’s compensation committee granted 37,900 Restricted Stock Units (RSUs) to six new non-executive employees. The awards were made under the company’s 2025 Employment Inducement Award Plan pursuant to Nasdaq Rule 5635(c)(4).
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 30 | Scientific presentation | Neutral | -4.6% | Announced a presentation covering two-year PRISM Phase 2b follow-up data. |
| Jun 29 | Phase 3 enrollment | Positive | +11.0% | Completed global enrollment in 4FRONT-2 ahead of projections with over-enrollment. |
| Jun 29 | Credit facility | Positive | +11.0% | Entered a Hercules Capital facility providing up to $200 million. |
| Jun 12 | Inducement grants | Negative | +4.4% | Granted 66,900 restricted stock units to seven new employees. |
| May 27 | Investor conferences | Neutral | +1.6% | Announced participation in two June investor healthcare conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
FDMT previously reacted positively to clinical and credit announcements, while its prior inducement-grant announcement preceded a 4.42% increase.
Key Terms
restricted stock units financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on July 14, 2026, the compensation committee of the Company’s board of directors granted six new non-executive employees 37,900 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, Backbone 4 Retina™ and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts: Media: Jenn Gordon dna Communications Media@4DMT.com Investors: Julian Pei Head of Investor Relations and Strategic Finance Investor.Relations@4DMT.com